Revance Therapeutics, Inc.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Report date

12/31/2024

Quarter

2024 Q4

Filed

2/14/2025

Shares

237,409

Value ($000)

722

Weight

0.0%

2014 Q1 - 2024 Q4 (22 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2024 Q4	2/14/2025	722	0.0%	237,409	12/31/2024
2024 Q3	11/14/2024	1,376	0.0%	265,210	9/30/2024
2024 Q2	8/14/2024	611	0.0%	237,790	6/30/2024
2024 Q1	5/15/2024	587	0.0%	119,361	3/31/2024
2023 Q4	2/14/2024	1,049	0.0%	119,361	12/31/2023
2023 Q3	11/13/2023	1,269	0.0%	110,675	9/30/2023
2023 Q2	8/11/2023	2,928	0.0%	90,914	6/30/2023
2023 Q1	5/15/2023	2,928	0.0%	90,914	3/31/2023
2022 Q4	2/14/2023	1,458	0.0%	78,986	12/31/2022
2022 Q3	11/14/2022	1,885	0.0%	69,815	9/30/2022
2022 Q2	8/12/2022	951	0.0%	68,832	6/30/2022
2022 Q1	5/16/2022	1,284	0.0%	65,831	3/31/2022
2021 Q4	2/14/2022	1,074	0.0%	65,831	12/31/2021
2021 Q3	11/15/2021	10,101	0.0%	362,548	9/30/2021
2021 Q2	8/16/2021	10,976	0.0%	370,294	6/30/2021
2021 Q1	5/14/2021	10,737	0.0%	384,156	3/31/2021
2020 Q4	3/1/2021	10,618	0.0%	374,676	12/31/2020
2020 Q3	11/13/2020	1,061	0.0%	42,223	9/30/2020
2020 Q2	8/14/2020	1,000	0.0%	40,935	6/30/2020
2020 Q1	5/15/2020	519	0.0%	35,064	3/31/2020
2019 Q4	2/14/2020	490	0.0%	30,165	12/31/2019
2014 Q1	5/23/2014	1,521	0.0%	48,300	3/31/2014